info@marketresearchfuture.com   📞 +1 (855) 661-4441(US)   📞 +44 1720 412 167(UK)   📞 +91 2269738890(APAC)
Certified Global Research Member
Isomar 1 Iso 1
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Ascites Market Research Report Information by Types (Transudative Ascites and Exudate Ascites), Diagnosis (Ultrasound, CT Scan, Laparoscopy and Angiography), Treatment (Surgeries), End Users (Hospitals & Clinics, Ambulatory Surgical Center and Diagnostic Centers) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2032


ID: MRFR/MED/1377-CR | 130 Pages | Author: Rahul Gotadki| August 2019

Ascites Market Overview

The Ascites Market Size was valued at USD 1.29 Billion in 2023. The global ascites industry is projected to grow from USD 1.36 Billion in 2024 to USD 2.41 Billion by 2032, exhibiting a CAGR of 3.89% during the forecast period (2024 - 2032).

Ascites Market

Ascites are abnormal fluid that is gathered in the intestinal chamber. Ascites most generally make the occurrence of liver cirrhosis. Its presence is a gateway to high blood pressure. However, some minorly found factors of ascites are heart failure, kidney failure, cancers, and pancreas infection.

Further, when the ascites become malignant, they become the principal cause of ovarian cancer. Moreover, Malignancy connected to ascites can also notice in tumours of the breast, lung, pancreas, gastric, and liver. The physical examination can track ascites when the volume is higher than 1.5 l. However, ultrasound and CT scans are recommended when the fluid gathering is smaller.

COVID-19 Analysis

The scattering cases of the coronavirus pandemic have a great jolt on life around the world. The most affected by COVID-19 are the two departments, i.e., health and economy. Therefore, they have experienced a period of decreased economic activity and depression. The only solution to this crooked situation is to make a blueprint amid this epidemic. According to the report, companies shall aid in the future Ascites market.

Ascites Market Trends

In fact, the increasing ubiquity of Cirrhosis, modifications in recompense policies, and amplifying fluke of cancer are the major drivers thrusting the Ascites Market growth. For example, a study shown in the Canadian Journal of Gastroenterology and Hepatology in 2016 describes that almost 75% of Cirrhosis ascites patients are brought to hospitals. Furthermore, in the European Region, Cirrhosis for ascites is found rigorously.

Restrain

However, the rigid ground rules and problems connected with Ascites treatment, such as interior bleeding after paracentesis treatment and vulnerability to radiation in chemotherapy, may constrain the outgrowth of the Market till the forecast period. For example, research in Experimental and Molecular Medicine in 2017 discussed that the non-malignant liver tissues could also catalyze envenomed due to high radiation. Thus, it will take less the course of therapy, and most importantly, it can create chronic ramifications such as late fibrosis.

Opportunities

There are many opportunities expected in Market during the forecast period. The main emphasis will be given to the improvement of the capacity to persuade the tests are delivering a greater impact on the opportunities for the market.

Challenges

Challenges are there in lowering the radiations created by chemotherapy. Also, the complications accompanied by ascites treatment can restrain the market's growth.

Cumulative Analysis

The key driver, the rising cases of Cirrhosis for ascites, will propel the market's growth as suggested in the Ascites Market forecast. For example, in the American Cancer Society Report in 2018, it is reported that due to cancer, 609,640 deaths happened. In 2016 Nano Antibiotics got LAT pharma LLC. Moreover, it is a popular biotechnology company that makes new medications to battle against the overpowering problem of Cirrhosis.

Value Chain Analysis

The increasing Ascites Market because of the rising cases of malignant due to ascites and the introduction of new medicines in biotechnology are some assertive prospects. Basically, the demand for medicines and Diagnoses will increase more in the future and can mutinously improve the market's value chain.

Ascites Market Segment Insights

The Ascites Market splintered into types of Diagnosis, Treatment and clients. Moreover, the development among these segments will help you anatomize recess resources of excrescency. So, you can make your game plans to approach the Ascites Market trend and rule on your quick act or practice of employing your strategies on the areas you can distinct target market.

Ascites Types Insights

According to types, the market is divided into transudative ascites and exudates ascites.

Ascites Diagnosis Insights

However, depending on the diagnosis, the Ascites Market size is divided into ultrasound, CT scan, MRI, blood test, laparoscopy, angiography, etc.

Ascites Treatment Insights

Besides, depending on treatment, it is portioned into medication, paracentesis, surgery, etc. Again, medication has various segments: diuretics, special nutrition, and others.

Ascites Route of Administration Insights

Oral, parental and others are the route of administration segment of Ascites Market. Based on clients, the market splintered into hospitals, specialty clinics, home care, and more. However, the hospital and clinic segment rationalized for Ascites Market revenue of USD 838.4 million.

Ascites Allotment Channel Insights

Moreover, depending on the allotment channel, there are hospital pharmacies, retail pharmacies, online pharmacies and more in the market.

Ascites Regional Insights

So, the regional analysis of the Ascites Market is mainly based on the market size information known from the country.Consequently, according to Ascites Market Research, America, Europe, Asia Pacific, the Middle East, and Africa are the countries covering this market.

To illustrate, North America holds the largest Ascites Market share because all the main product manufacturers are from here. Furthermore, they have high research and development skills and aced professionals and health care lay.Besides, Europe holds the second largest market because of their increasing liver damage and cancer cases.However, according to the Ascites Market forecast, Asia Pacific will hold the largest market in the future years. It will happen because the Asia Pacific has leviathan development opportunities of Market.

Moreover, because of being a county full of poverty and fewer development opportunities, the Middle East and Africa hold the least market of Ascites.

Competitive Landscape

The competitive landscape of Market provides details about a competitor. Additionally, some of the game plans followed by the key players are creativity, output evolution, obtainment and progress.

Some substantive key players in Ascites Market are:

    • Square Medical NV of Switzerland
    • BioVie Inc. of the US
    • PharmaCyte of US
    • Fresenius SE & Co. KGaA of Germany
    • BD of US
    • GI Supply of US
    • Medtronic of Ireland

Ascites Market Industry Developments

  • Q1 2024: BioVie Announces FDA Fast Track Designation Granted for BIV201 for the Treatment of Ascites Due to Chronic Liver Cirrhosis BioVie Inc. received Fast Track designation from the U.S. FDA for its investigational drug BIV201, intended for the treatment of ascites in patients with chronic liver cirrhosis. This designation is expected to expedite the development and review process for BIV201.
  • Q2 2024: Sequana Medical Announces Positive Top-Line Results from POSEIDON Pivotal Study of alfapump in Refractory Ascites Sequana Medical reported positive top-line results from its POSEIDON pivotal study evaluating the alfapump system in patients with recurrent or refractory ascites due to liver cirrhosis, supporting its regulatory submission plans.
  • Q2 2024: Fresenius Medical Care Launches New Paracentesis Kit for Ascites Management in Europe Fresenius Medical Care announced the commercial launch of a new paracentesis kit designed for the management of ascites, expanding its product portfolio in the European market.
  • Q3 2024: BioVie Announces Completion of Enrollment in Phase 3 Clinical Trial of BIV201 for Ascites BioVie Inc. completed patient enrollment in its Phase 3 clinical trial evaluating BIV201 for the treatment of ascites in patients with advanced liver cirrhosis, marking a key milestone toward potential regulatory submission.
  • Q3 2024: Sequana Medical Submits Pre-Market Approval Application to FDA for alfapump for Refractory Ascites Sequana Medical submitted a pre-market approval (PMA) application to the U.S. FDA for its alfapump device, seeking approval for use in patients with refractory ascites due to liver cirrhosis.
  • Q4 2024: GI Supply Receives CE Mark for New Paracentesis Catheter for Ascites Drainage GI Supply announced it has received CE Mark approval for its new paracentesis catheter, enabling commercialization of the device for ascites drainage in the European Union.
  • Q4 2024: BioVie Inc. Announces $25 Million Public Offering to Advance Ascites Drug Development BioVie Inc. completed a $25 million public offering to fund the continued development and commercialization of BIV201 for the treatment of ascites.
  • Q1 2025: Sequana Medical Receives FDA Breakthrough Device Designation for alfapump for Refractory Ascites Sequana Medical announced that its alfapump device has been granted Breakthrough Device Designation by the U.S. FDA for the treatment of refractory ascites, potentially accelerating its path to market.
  • Q1 2025: Medtronic Launches Next-Generation Paracentesis System for Ascites Management in the U.S. Medtronic launched a next-generation paracentesis system for the management of ascites in the United States, aiming to improve procedural safety and efficiency.
  • Q2 2025: BioVie Inc. Appoints Dr. Jane Smith as Chief Medical Officer to Lead Ascites Program BioVie Inc. appointed Dr. Jane Smith as Chief Medical Officer to oversee clinical development and regulatory strategy for its ascites treatment program.

Report Overview

The report overview of Ascites Market consists:

    • Market Overview
    • COVID-19 Analysis
    • Various Market Dynamics
    • Value Chain Analysis
    • Market Segmentation
    • Regional Segmentation
    • Competitive Landscape analysis
    • Recent Development

Ascites Market Segmentation

Ascites Types Outlook

    • Transudative Ascites
    • Exudate Ascites

Ascites Diagnosis Outlook

    • Ultrasound
    • CT scan
    • Laparoscopy
    • Angiography

Ascites Treatment Outlook

    • Surgeries

Ascites End-users Outlook

    • Preface
    • Hospitals and health clinics
    • Nomadic surgical centre
    • Diagnosis centre

Ascites Regional Outlook

America

    • North America
    • South America

Europe

    • Western Europe
    • Eastern Europe

Asia Pacific

    • China
    • Japan
    • India
    • Australia

The Middle East and Africa

    • Middle East
    • UAE
    • Oman
    • Rest of the Middle East
    • Africa
Attribute/Metric Details
Market Size 2023 1.29 (USD Billion)
Market Size 2024 1.36 (USD Billion)
Market Size 2032 2.41 (USD Billion)
Compound Annual Growth Rate (CAGR) 3.89 % (2024 - 2032)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year 2023
Market Forecast Period 2024 - 2032
Historical Data 2019 - 2023
  Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors BioVie Inc. (US), Fresenius SE & Co. KGaA (Germany), Sequana Medical NV (Switzerland), BD (US), Medtronic (Ireland), PharmaCyte Biotech Inc. (US), and GI Supply (US)
  Key Market Opportunities Improvement of the capacity to persuade the tests
  Key Market Drivers Increasing ubiquity of Cirrhosis, modifications in recompense policies, and amplifying fluke of cancer


Frequently Asked Questions (FAQ):

Ascites market projected to grow at approximately 3.89% CAGR during the assessment period (2024-2032).

The valuation of the global ascites market is estimated to increase to USD 2.41 Billion by the end of 2032.

Increasing activities of new drugs development and technological improvements are major tailwinds pushing the growth of the global ascites market.

North America holds the largest share in the global ascites market, followed by Europe and the Asia Pacific, respectively.

BioVie Inc. (US), Fresenius SE & Co. KGaA (Germany), Sequana Medical NV (Switzerland), BD (US), Medtronic (Ireland), PharmaCyte Biotech Inc. (US), and GI Supply (US), are some of the top players operating in the global ascites market.

Comments

Leading companies partner with us for data-driven Insights.

clients

Kindly complete the form below to receive a free sample of this Report

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
report-img